Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesDurable Medical Equipment (DME)Bluecross Idaho Stimulation Policy Update | OpenPa…
    Ask Trek AI about this page
    CurrentBluecross IdahoPolicy MP 1.01.507

    Electrical Stimulation Devices for Pain Control

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy MP 1.01.507 alerts

    Get alerted when Policy MP 1.01.507 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage of electrical, electromagnetic, and related stimulation devices used for pain control and other indications under the Durable Medical Equipment benefit.

    Policy Summary
    PayerBluecross Idaho
    PolicyElectrical Stimulation Devices for Pain Control
    Policy CodePolicy N/A
    Change TypeAnnual review — no material change
    Effective DateNov 19, 2026
    Last ReviewNov 19, 2026
    Next Review DateN/A
    Key ActionFor Calmare therapy, document direct supervision by a qualified, licensed, certified healthcare professional familiar with the device’s applications, side effects, and hazards.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    8Investigational technologies or indications
    InvestigationalMicrocurrent stimulation
    Insufficient evidenceH-wave stimulation
    Non-coveredMedicare coverage
    3Related policies

    Coverage Criteria

    Investigational electrical stimulation devices and indications

    The following technologies or indications are considered investigational.

    Investigational electrical stimulation technologies

    • Specified investigational categories: The requested therapy falls within one of the electrical or electromagnetic stimulation categories identified above.

      Examples named in the policy include FastStart HVPC, HWAVE Muscle Stimulator, Alpha Stim, ClearUP Sinus Pain Relief, Myopulse 75C, Electro-Myopulse 75L, Monarch eTNS, and Calmare.

    H-wave stimulation

    The evidence is insufficient to establish effectiveness.

    H-wave stimulation: H-wave electrical stimulation is not supported by sufficient reliable evidence to establish its effect on net health outcomes.

    Available studies are small or methodologically limited, and systematic review findings have been questioned.

    Monarch eTNS

    The evidence is insufficient to support treatment.

    Monarch eTNS for pediatric ADHD: External trigeminal nerve stimulation is not supported for treatment of attention deficit hyperactivity disorder in children based on the available evidence.

    Validation with larger, well-designed studies is needed.

    Microcurrent stimulation

    Microcurrent stimulation remains investigational.

    Microcurrent electrical nerve stimulation: Microcurrent stimulation is investigational because adequate large controlled clinical trials against placebo devices are lacking.

    The cited study did not establish durable effects or continued benefit with repeated use.

    Pulsed electrical and electromagnetic stimulation

    Pulsed electrical or electromagnetic stimulation is considered investigational for osteoarthritis and rheumatoid arthritis.

    Arthritis treatment: Pulsed electrical or electromagnetic stimulation is investigational for osteoarthritis and rheumatoid arthritis because sufficient proof of efficacy and improvement in health outcomes has not been established.

    Evidence is limited by heterogeneous treatment protocols, small samples, suboptimal study designs, inconsistent results, and lack of identified studies for rheumatoid arthritis.

    The following technologies and indications are considered investigational: electrical sympathetic stimulation therapy devices; galvanic or high-voltage galvanic stimulation for chronic pain; H-wave stimulation for chronic, acute, or postoperative pain; microcurrent electrical nerve stimulation (MENS) devices; external trigeminal nerve stimulation for ADHD; pulsed electrical stimulation or pulsed electromagnetic therapy for any indication; and transcutaneous electrical modulation pain reprocessing (TEMPR), also known as Scrambler or Calmare therapy.

    Pulsed electrical or electromagnetic stimulation is considered investigational for osteoarthritis and rheumatoid arthritis. Evidence is also inadequate for wound healing, pressure ulcers, diabetic peripheral neuropathy, and other pain-related uses because studies are limited by small samples, heterogeneous treatment protocols, methodological limitations, inconsistent results, and insufficient evidence of improved health outcomes.

    External trigeminal nerve stimulation, including the Monarch eTNS system, is considered investigational for treatment of ADHD in children. Available evidence is insufficient to support treatment, and validation in larger, well-designed studies is needed.

    Coding Information

    FDA product codesmixed
    PQYFDA product code for ActiPatch
    NYNFDA product code for the BioniCare Bio-1000 stimulator
    FDA product and 510(k) referencesmixed
    ILXFDA product code for the OrthoCor Active Knee System and SofPulse/related short-wave diathermy devices
    K091996FDA 510(k) clearance reference for the OrthoCor Knee System
    K092044FDA 510(k) clearance reference for the OrthoCor Knee System
    K091640Predicate device reference for the OrthoCor system
    K070541FDA 510(k) clearance reference for Ivivi Torino II/SofPulse
    CPTCPT
    0278TTranscutaneous electrical modulation pain reprocessing (e.g., scrambler therapy), each treatment session (includes placement of electrodes) (code may be used for Scrambler therapy or Calmare® pain therapy).
    HCPCSHCPCS
    A4541Monthly supplies for use of device coded at E0733.
    E0733Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve (e.g., Monarch® eTNS).
    E0762Transcutaneous electrical joint stimulation device system, includes all accessories.
    E1399Durable medical equipment, miscellaneous

    Provider Actions and Denial Considerations

    Documentation Required

    Calmare® Supervision and Provider Qualifications

    Calmare® treatment may be performed only under the direct supervision of an allopathic physician or other qualified, licensed healthcare professional who is certified in its use and application. The supervising provider must be familiar with the principles, clinical applications, side effects, and hazards of transdermal pain modulation.

    Denial Risk

    Investigational Electrical and Electromagnetic Technologies

    Electrical sympathetic stimulation therapy, galvanic or high-voltage galvanic stimulation for chronic pain, H-wave stimulation, microcurrent electrical nerve stimulation, external trigeminal nerve stimulation for pediatric ADHD, pulsed electrical stimulation, pulsed electromagnetic therapy, and TEMPR (Scrambler or Calmare® therapy) are considered investigational. Coverage may be denied for these technologies or indications.

    • Examples include FastStart HVPC, HWAVE® Muscle Stimulator, Alpha Stim, ClearUP™ Sinus Pain Relief, Myopulse 75C, Electro-Myopulse 75L, and Monarch® eTNS.

    Medical Necessity

    Investigational stimulation equipment

    The equipment or therapy is considered investigational when it falls within any of the specified categories.

    Investigational DME categories: The requested DME is an electrical or electromagnetic stimulation device identified as investigational by this policy.

    Categories include electrical sympathetic stimulation therapy devices; galvanic or high-voltage galvanic stimulation for chronic pain; H-wave stimulation for chronic, acute, or postoperative pain; microcurrent electrical nerve stimulation devices; external trigeminal nerve stimulation for attention deficit hyperactivity disorder; pulsed electrical stimulation or pulsed electromagnetic therapy for any indication; and transcutaneous electrical modulation pain reprocessing, Scrambler therapy, or Calmare pain therapy. FDA clearance, approval, or marketing status does not by itself establish coverage or medical necessity.

    Calmare supervision

    When Calmare therapy is provided, the treatment setting and personnel must meet the following requirement.

    Calmare treatment supervision: Treatment must occur under the direct supervision of an allopathic physician or other qualified licensed healthcare professional certified in Calmare use and application and familiar with transdermal pain modulation principles, clinical applications, side effects, and hazards.

    Documentation Requirements

    Documentation Required

    Provide Calmare under qualified direct supervision

    Calmare treatment must be performed under the direct supervision of an allopathic physician or other qualified licensed healthcare professional who is certified in its use and application and familiar with the principles, clinical applications, side effects, and hazards associated with transdermal pain modulation.

    • Document the professional’s licensure and certification in Calmare use and application.
    • Confirm direct supervision during treatment.

    Background

    This policy addresses electrical and electromagnetic stimulation technologies proposed for pain relief, edema reduction, tissue healing, and other clinical indications. Coverage is limited for the technologies and uses identified as investigational because the available evidence is limited, low quality, inconsistent, or insufficient to establish improved net health outcomes. FDA clearance, approval, or marketing authorization does not independently establish coverage or medical necessity.

    Definitions

    Galvanic stimulation
    Stimulation typeHigh-voltage, pulsed stimulation
    Primary useLocal edema reduction
    Proposed mechanismsMuscle pumping and polarity effects
    Microcurrent electrical nerve stimulation (MENS)
    CurrentSubsensory current
    Proposed purposeDecrease pain and facilitate the healing process by acting on naturally occurring electrical impulses
    Difference from TENSUses a significantly reduced level of electrical stimulation; TENS blocks pain, while MENS acts on naturally occurring electrical impulses

    Not Covered Services

    The following are not covered when addressed by this policy: electrical sympathetic stimulation therapy devices; galvanic or high-voltage galvanic stimulation for chronic pain; H-wave stimulation for chronic, acute, or postoperative pain; microcurrent electrical nerve stimulation devices; external trigeminal nerve stimulation for ADHD; pulsed electrical stimulation and pulsed electromagnetic therapy for any indication, including arthritis, neuropathic pain, postoperative or non-postoperative pain, and wound treatment; and TEMPR, Scrambler therapy, or Calmare pain therapy.

    Policy Summary
    PayerBluecross Idaho
    PolicyElectrical Stimulation Devices for Pain Control
    Policy CodePolicy N/A
    Change TypeAnnual review — no material change
    Effective DateNov 19, 2026
    Last ReviewNov 19, 2026
    Next Review DateN/A
    Key ActionFor Calmare therapy, document direct supervision by a qualified, licensed, certified healthcare professional familiar with the device’s applications, side effects, and hazards.
    SourceLink
    On This Page
    Coverage CriteriaCoding InformationProvider Actions and Denial ConsiderationsMedical NecessityDocumentation RequirementsBackgroundDefinitionsNot Covered Services
    Note

    Member Benefit Plan Controls

    Coverage remains subject to the member-specific benefit plan and all applicable terms, conditions, limitations, and exclusions. Applicable federal or state law may control whether an FDA-approved or cleared technology is considered investigational, but a determination that it is not investigational does not by itself establish coverage or medical necessity.

    Denial Risk

    Insufficient Evidence for H-Wave Stimulation

    H-wave electrical stimulation is considered investigational for chronic, acute, or postoperative pain because the available evidence is insufficient to draw conclusions about its effect on net health outcomes.

    • Existing randomized controlled trials are small, and systematic-review findings are limited by methodological concerns and reported conflicts of interest.
    Denial Risk

    Monarch® eTNS for Pediatric ADHD

    External trigeminal nerve stimulation, including the Monarch® eTNS system, is considered investigational for treating ADHD in children. Current evidence is insufficient, and validation in larger, well-designed studies is needed.

    Denial Risk

    Microcurrent Stimulation Is Investigational

    Microcurrent electrical nerve stimulation (MENS) devices are considered investigational because large controlled clinical trials against placebo devices are lacking and durability of treatment effects has not been established.

    • Examples include Alpha Stim, ClearUP™ Sinus Pain Relief, Myopulse 75C, and Electro-Myopulse 75L.
    Denial Risk

    Pulsed and Electromagnetic Stimulation

    Pulsed electrical stimulation and pulsed electromagnetic therapy are considered investigational because evidence is inadequate or insufficient to establish improvements in health outcomes. This applies to osteoarthritis, rheumatoid arthritis, wound healing, and other indications, including neuropathic pain such as diabetic peripheral neuropathy.

    • Evidence for arthritis is limited by small samples, heterogeneous treatment protocols, inconsistent results, and methodological limitations.
    • Evidence for wound healing and pressure ulcers does not demonstrate benefit; evidence for other conditions is mainly mixed case-series or limited randomized-trial data.
    • Published guidelines do not support electromagnetic field therapy for peripheral diabetic neuropathy.
    Billing Rule

    Medicare Non-Coverage

    The codes in this policy are non-covered for Medicare. Refer to Noridian Local Coverage Determination Transcutaneous Electrical Joint Stimulation Devices (TEJSD) L34821.

    This is an administration and provider qualification requirement, not evidence of clinical effectiveness.

    Pulsed electrical and electromagnetic stimulation
    Field typeWeak electrical or magnetic fields
    DeliveryNoninvasive delivery through electrodes, capacitive coupling, treatment coils, or combined magnetic fields
    Proposed usesImprove functional status and relieve pain related to osteoarthritis and rheumatoid arthritis that are unresponsive to other standard therapies
    Transcutaneous electrical modulation pain reprocessing (TEMPR)
    ElectrodesDisposable surface electrodes applied to the skin in the region of the patient's pain
    Purported mechanismTransmits a purported "no-pain" message to the nerve through the same pathway as pain signals
    Treatment approachUses a biophysical rather than a biochemical approach
    Transcutaneous Electrical Modulation Pain Reprocessing (TEMPR)
    Also known asScrambler Therapy or Calmare® therapy
    Device typeElectrocutaneous nerve stimulation device
    Electrode useUses disposable surface electrodes applied to the skin in the region of the patient's pain
    Purported effectTransmits a purported "no-pain" message that replaces the pain message through the same pathway
    H-wave electrical stimulation
    Therapy typeTranscutaneous electrotherapy
    WaveformUses a waveform different from other types of electrical stimulation
    Evidence statusEvidence is insufficient to draw conclusions about the effect on the net health outcome
    Monarch external trigeminal neurostimulation (eTNS)
    Intended useMonotherapy for attention deficit hyperactivity disorder (ADHD)
    Patient populationPediatric patients ages 7 to 12 years old
    Medication statusFor patients who are not taking prescription ADHD medications
    AccessAvailable by prescription only